Cargando…

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial

BACKGROUND: An urgent need exists to rapidly screen potential therapeutics for severe COVID-19 or other emerging pathogens associated with high morbidity and mortality. METHODS: Using an adaptive platform design created to rapidly evaluate investigational agents, hospitalised patients with severe CO...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981330/ https://www.ncbi.nlm.nih.gov/pubmed/36883141 http://dx.doi.org/10.1016/j.eclinm.2023.101889

Ejemplares similares

I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations
por: Files, Daniel Clark, et al.
Publicado: (2022)

SpiNNTools: The Execution Engine for the SpiNNaker Platform
por: Rowley, Andrew G. D., et al.
Publicado: (2019)

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
por: Hayward, Gail, et al.
Publicado: (2021)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
por: Yu, Ly-Mee, et al.
Publicado: (2021)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Publicado: (2022)

STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol
por: Forshaw, Denise, et al.
Publicado: (2023)

Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension
por: Montgomery, Paul, et al.
Publicado: (2018)

Catching a SPY: Using the SpyCatcher-SpyTag and Related Systems for Labeling and Localizing Bacterial Proteins
por: Hatlem, Daniel, et al.
Publicado: (2019)

Seven myths of randomisation in clinical trials
por: Senn, Stephen
Publicado: (2011)

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2020)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Publicado: (2021)

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
por: Birtle, Alison, et al.
Publicado: (2020)

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
por: Jittamala, Podjanee, et al.
Publicado: (2023)

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
por: Butler, Christopher C, et al.
Publicado: (2021)

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
por: Gbinigie, Oghenekome, et al.
Publicado: (2023)

Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: The SPiRiT trial
por: Dyer, M T, et al.
Publicado: (2008)

Randomised Ambulatory Management of Primary Pneumothorax (RAMPP): protocol of an open-label, randomised controlled trial
por: Hallifax, Rob, et al.
Publicado: (2019)

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
por: Ledgerwood, Julie E, et al.
Publicado: (2011)

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)
por: Schilling, William HK, et al.
Publicado: (2023)

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Publicado: (2021)

Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial
por: Hallifax, Rob J, et al.
Publicado: (2020)

Spray on skin for diabetic foot ulcers: an open label randomised controlled trial
por: Manning, Laurens, et al.
Publicado: (2019)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Publicado: (2022)

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Publicado: (2020)

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
por: Agarwal, Anup, et al.
Publicado: (2020)

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
por: Madhavan, Meera, et al.
Publicado: (2022)

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
por: Ellis, Paul, et al.
Publicado: (2009)

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
por: Ramakrishnan, Sanjay, et al.
Publicado: (2021)

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial
por: Wallis, Robert S, et al.
Publicado: (2021)

Yoga as an Adjuvant therapy in management of migraine- An open label randomised trial
por: Kumari, Sweety, et al.
Publicado: (2022)

Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial
por: Patil, Vijay M., et al.
Publicado: (2022)

First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
por: Smit, Merel J, et al.
Publicado: (2023)

A trial like ALIC(4)E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness?
por: Butler, Christopher C., et al.
Publicado: (2018)

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
por: Dorward, Jienchi, et al.
Publicado: (2022)

Inased (inhaled sedation in ICU) trial protocol: a multicentre randomised open-label trial
por: Bailly, Pierre, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qklpl5o9nm7ajeo55kcnlhpqjn